{"type":"trials","record":{"id":41367,"source_id":"clinicaltrials-gov","external_id":"NCT07441642","title":"A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","brief_summary":"To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":272,"countries":["United States","Australia","Bulgaria","Canada","Colombia","Czechia","France","Germany","Hungary","Italy","Japan","Poland","Puerto Rico","Romania","Spain","United Kingdom"],"start_date":"2026-03-09","completion_date":"2029-08-22","last_update_date":"2026-09-09","source_url":"https://clinicaltrials.gov/study/NCT07441642","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Placebo","organization":"Novartis","interventions":["FWY003","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change of geographic atrophy (GA) lesion area in the study eye — From Baseline to Month 18","Number of participants with adverse events (AEs) and serious adverse events (SAEs) — From first dose (Day 1) to Month 19","Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye — B…","Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye — Baseline through Month…","Change in visual function measure by Quantitative contrast sensitivity function (qCSF) under regular luminance in the s…","Change in visual function measure by Low Contrast quantitative Visual Acuity (LCqVA) under regular luminance in the stu…","Change in visual function measure by LCqVA under low luminance in the study eye — Baseline through Month 18","Proportion of participants with ≥15 letters loss — Baseline through Month 18","Change in area of total and partial ellipsoid zone (EZ) attenuation in the macula in the study eye — Baseline through M…","Plasma concentrations of FWY003 — Baseline through Month 18","Rate of change of GA lesion area (square-root transformed) in the study eye — Baseline through Month 18","Change of GA lesion area (square-root transformed) — Baseline through Month 12"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Geographic Atrophy Secondary to Age-related Macular Degeneration","FWY003","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07441642","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-03-09 to 2029-08-22","comparator":"Placebo","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.800Z","intervention":["FWY003","Placebo"],"participants":272,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change of geographic atrophy (GA) lesion area in the study eye — From Baseline to Month 18","Number of participants with adverse events (AEs) and serious adverse events (SAEs) — From first dose (Day 1) to Month 19","Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye — B…","Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye — Baseline through Month…","Change in visual function measure by Quantitative contrast sensitivity function (qCSF) under regular luminance in the s…","Change in visual function measure by Low Contrast quantitative Visual Acuity (LCqVA) under regular luminance in the stu…","Change in visual function measure by LCqVA under low luminance in the study eye — Baseline through Month 18","Proportion of participants with ≥15 letters loss — Baseline through Month 18","Change in area of total and partial ellipsoid zone (EZ) attenuation in the macula in the study eye — Baseline through M…","Plasma concentrations of FWY003 — Baseline through Month 18","Rate of change of GA lesion area (square-root transformed) in the study eye — Baseline through Month 18","Change of GA lesion area (square-root transformed) — Baseline through Month 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41367","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}